01 14Adempas
02 2Alliance revenue - Adempas/Verquvo
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 760
2019 Revenue in Millions : 506
Growth (%) : 50
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 501
2019 Revenue in Millions : 419
Growth (%) : 20
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 813
2020 Revenue in Millions : 760
Growth (%) : 18
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 252
2020 Revenue in Millions : 220
Growth (%) : 15
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 685
2021 Revenue in Millions : 813
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 238
2021 Revenue in Millions : 252
Growth (%) : -6
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 341
2021 Revenue in Millions : 342
Growth (%) : -0.3
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 716
2022 Revenue in Millions : 685
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 367
2022 Revenue in Millions : 341
Growth (%) : 7.6
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 255
2022 Revenue in Millions : 238
Growth (%) : 7
LOOKING FOR A SUPPLIER?